Hormonal Contraception and Heart Risk: What 10 Million Women Should Know

Combined oral contraceptives are used by 10 million American women. Modern low-dose formulations carry a VTE incidence of 9-10 per 10,000 woman-years, a threefold increase from baseline. For women with migraine with aura, the stroke risk multiplies sixfold. The 2024 U.S. Medical Eligibility Criteria now classify certain populations as Category 4 contraindications, meaning unacceptable health risk. This article provides the specific risk figures by formulation, progestin type, and individual risk factor that determine whether hormonal contraception is appropriate for you.

Low-dose means low risk. That was the message. For most women, it is correct. For a woman with migraine aura, smoking history, or Factor V Leiden, it is not.

I prescribed oral contraceptives to a 34-year-old woman last year after a routine visit. Her blood pressure was 118/76. She exercised four times weekly. Her lipid panel was pristine. Three months later, she developed deep vein thrombosis in her left leg. When we tested her, she carried Factor V Leiden heterozygosity. A single genetic variant she did not know she had increased her VTE risk on combined contraceptives from 9 per 10,000 to 50 per 10,000.

She asked me a question I could not answer satisfactorily: “Why didn’t anyone test me before starting the pill?”

The honest answer is that we do not test everyone. Universal thrombophilia screening is not cost-effective at the population level. But that population-level calculation offered little comfort to a woman with a clot in her leg. The clinical challenge of hormonal contraception is precisely this gap between reassuring population statistics and the individual woman in the exam room.

The Vascular Pharmacology of Estrogen

Combined oral contraceptives contain two hormones: a synthetic estrogen (almost always ethinyl estradiol) and a synthetic progestin. The estrogen component drives nearly all cardiovascular risk.

Ethinyl estradiol induces hepatic synthesis of clotting factors. Specifically, it increases factors II, VII, VIII, and X while decreasing the natural anticoagulants protein S and antithrombin. This shifts the hemostatic balance toward thrombosis. Brabaharan S, et al. 2022 5 / Solid

The dose matters. The original 1960s formulations contained 50-150 micrograms of estrogen. Modern low-dose pills contain 20-35 micrograms. This reduction explains the dramatic improvement in safety. A dose-response meta-analysis in Frontiers in Neurology found that each 10-microgram reduction in ethinyl estradiol decreases ischemic stroke risk by approximately 15%. Zhang C, et al. 2019 4 / Promising

But low-dose does not mean no-dose. Even 20 micrograms of ethinyl estradiol produces measurable changes in coagulation parameters within the first month of use.

The progestin component modifies this risk. Different progestins have different androgenic and mineralocorticoid profiles. These profiles affect blood pressure, lipids, and thrombotic tendency in distinct ways. I will address progestin-specific risks in a dedicated section below.

Transdermal and vaginal ring formulations still contain estrogen. The NuvaRing delivers approximately 15 micrograms of ethinyl estradiol daily. The patch delivers 20 micrograms daily but with higher peak serum levels than oral formulations. Neither route eliminates estrogen-related risk.

The Numbers That Define Your Risk

Baseline VTE incidence in reproductive-age women not using hormonal contraception is 3-4 per 10,000 woman-years. Combined oral contraceptive use raises this to 9-10 per 10,000 woman-years. This represents a threefold relative risk increase. Lidegaard Ø, et al. 2009 5 / Solid

Context matters. Pregnancy carries a VTE incidence of 29 per 10,000 woman-years. The postpartum period carries a risk of 300-400 per 10,000 woman-years in the first six weeks. Hormonal contraception is safer than pregnancy for vascular outcomes.

But 9 per 10,000 is not zero. In a population of 10 million American women using combined oral contraceptives, this translates to approximately 9,000 venous thromboembolic events annually that would not have occurred without the medication.

The 2025 BMJ nationwide prospective cohort study quantified arterial events with contemporary formulations. Among current users of combined oral contraceptives, there were 6.9 additional ischemic strokes and 3.2 additional myocardial infarctions per 100,000 person-years compared to non-users. Vinther Skriver M, et al. 2025 5 / Solid

These absolute numbers appear small. For a healthy 25-year-old woman with no risk factors, they are small. The question is whether you have risk factors that multiply these baseline figures.

The Contraceptive Risk Stratification Framework provides a systematic approach. I use this framework in my practice to identify women who require either additional testing, alternative methods, or absolute contraindication to estrogen.

The Contraceptive Risk Stratification Framework

Not every woman can safely use combined hormonal contraception. The 2024 U.S. Medical Eligibility Criteria (MEC) classify contraceptive methods into four categories based on individual risk factors. Curtis KM, et al. 2024

Category 1: No restriction. Use the method in any circumstance. Category 2: Advantages generally outweigh risks. Use with follow-up. Category 3: Risks usually outweigh advantages. Use only if no other suitable method available and with careful monitoring. Category 4: Unacceptable health risk. Do not use.

Combined oral contraceptives carry Category 4 contraindications in the following populations:

Migraine with aura at any age. The odds ratio for ischemic stroke in women with migraine with aura using COCs is 6.1 compared to non-users without aura. MacGregor EA, et al. 2010 This sixfold increase makes estrogen-containing contraception unacceptable in this population.

Systolic blood pressure 160 mmHg or greater. Diastolic blood pressure 100 mmHg or greater. Uncontrolled hypertension plus estrogen creates a stroke risk that outweighs any contraceptive benefit.

Current or past VTE. History of pulmonary embolism. Known thrombophilia including Factor V Leiden, prothrombin gene mutation, protein C deficiency, protein S deficiency, or antithrombin deficiency.

Smoking 15 or more cigarettes daily in women over age 35. The combination of age, smoking, and estrogen multiplies cardiovascular risk multiplicatively, not additively.

Active breast cancer. Estrogen-receptor-positive breast cancer is hormone-sensitive.

Major surgery with prolonged immobilization. The combination of surgical stress, immobility, and hypercoagulable state from estrogen creates unacceptable VTE risk.

Complicated valvular heart disease including pulmonary hypertension, atrial fibrillation, or history of subacute bacterial endocarditis.

Category 3 contraindications include smoking fewer than 15 cigarettes daily in women over 35, controlled hypertension on medication, migraine without aura in women over 35, and history of gestational diabetes with subsequent vascular disease.

Women don’t die from what they have. Women die from what they hold. A woman holds her birth control prescription, trusting that someone assessed whether it was safe for her specific body, her specific history, her specific genetics. Often, no one did.

The Progestin Problem: Why Your Specific Pill Matters

All progestins are not equal. The progestin component of combined oral contraceptives significantly modifies VTE risk.

Levonorgestrel is a second-generation progestin with androgenic properties. Combined oral contraceptives containing levonorgestrel have a VTE incidence of 6-8 per 10,000 woman-years. This is double the baseline risk of 3-4 per 10,000, but it represents the lowest VTE risk among estrogen-containing options.

Drospirenone is a newer progestin with anti-mineralocorticoid properties. It reduces water retention and can modestly lower blood pressure. However, combined oral contraceptives containing drospirenone have a VTE incidence of 10-12 per 10,000 woman-years. Dinger J, et al. 2011 5 / Solid

Desogestrel is a third-generation progestin. It also carries a VTE incidence of 10-12 per 10,000 woman-years, similar to drospirenone.

Gestodene carries comparable elevated risk.

The practical implication is clear. If you require estrogen-containing contraception and have no contraindications, choose a levonorgestrel-containing formulation. Examples include Alesse, Levlen, Portia, and generic levonorgestrel/ethinyl estradiol combinations.

The marketing of newer progestins emphasizes cosmetic benefits: less bloating, clearer skin, reduced premenstrual symptoms. These benefits are real. They are not worth a 50% increase in blood clot risk for most women.

The 2024 MEC update also flagged a new signal regarding depot medroxyprogesterone acetate (DMPA), the injectable progestin-only contraceptive. Emerging data suggest possible increased VTE risk with DMPA, though the mechanism differs from estrogen-related risk. This finding remains under investigation, and current guidelines have not changed DMPA’s Category 1 status for most women. 3 / Early

Progestin-Only and Non-Hormonal Options: The Cardiovascular-Neutral Alternatives

Progestin-only methods do not increase VTE or stroke risk. This finding is strong across multiple large cohort studies.

The progestin-only pill (the “minipill”) has a relative risk of VTE of 0.90 compared to non-users. This means no increased risk. Lidegaard Ø, et al. 2011 5 / Solid

The levonorgestrel-releasing intrauterine system (LNG-IUS, sold as Mirena, Liletta, Kyleena, and Skyla) has a relative risk of VTE of 0.6 compared to non-users. This means potentially lower risk, though the confidence interval includes 1.0. Regardless, there is no increased cardiovascular risk.

The etonogestrel implant (Nexplanon) shows no association with VTE or arterial events in available data.

The copper intrauterine device (ParaGard) contains no hormones. It cannot affect cardiovascular parameters by definition.

For women with Category 4 contraindications to combined hormonal contraception, these options provide highly effective pregnancy prevention without cardiovascular risk. The LNG-IUS is more effective than combined oral contraceptives. The implant is more effective than combined oral contraceptives. Both require no daily action.

The clinical question I ask women with cardiovascular risk factors is this: “Do you need the estrogen, or do you need the contraception?”

If you need contraception, progestin-only methods and the copper IUD provide it without vascular risk.

If you specifically need estrogen for cycle regulation or hormonal symptoms, the calculation becomes different. In that case, you need careful risk stratification and possibly a transdermal formulation to minimize clotting factor induction. See our detailed analysis in MHT Types Comparison: Transdermal vs. Oral.

The Special Populations: Migraines, Autoimmune Disease, and Perimenopause

Three populations require particular attention in contraceptive cardiovascular risk assessment.

Women with migraine require distinction between migraine with and without aura. This distinction is not academic. It is the difference between Category 2 and Category 4.

Migraine without aura does not contraindicate combined oral contraceptives in women under 35 who do not smoke. The evidence shows no significant stroke risk increase in this population.

Migraine with aura contraindicates all estrogen-containing contraception. The sixfold stroke risk increase applies regardless of age, frequency of aura, or other factors. If you experience visual disturbances, sensory changes, or language difficulty before your headaches, you have aura. If you are unsure, err on the side of caution and avoid estrogen. For detailed guidance, see Migraines with Aura and Stroke Risk in Women.

Women with autoimmune disease, particularly systemic lupus erythematosus (SLE) with antiphospholipid antibodies, have dramatically elevated baseline thrombotic risk. Adding estrogen to this substrate is Category 4. Women with SLE but without antiphospholipid antibodies may use combined contraception if their disease is stable and they have no other contraindications. The assessment requires collaboration between rheumatology and gynecology. See Autoimmune Disease and Cardiac Risk in Women.

Women in perimenopause present a unique challenge. The average age of menopause is 51. The perimenopausal transition typically begins 4-8 years earlier. During this time, cardiovascular risk accelerates due to declining endogenous estrogen and the shift to a more atherogenic lipid profile.

Perimenopausal women may still need contraception. Fertility persists until 12 consecutive months without menses. But perimenopausal women are also older and more likely to have developed hypertension, obesity, or other cardiovascular risk factors.

Combined oral contraceptives in healthy non-smoking women over 35 remain Category 2. But the margin for error narrows. Blood pressure monitoring should occur more frequently. The progestin choice matters more. The transition to progestin-only methods or non-hormonal options becomes more attractive as baseline cardiovascular risk rises.

For a complete discussion of cardiovascular risk during the menopausal transition, see Perimenopause and Cardiovascular Risk.

What to Ask Before Starting Hormonal Contraception

The prescription pad comes out too quickly. A complete cardiovascular assessment before initiating combined hormonal contraception should include the following elements.

Blood pressure measurement. Not just once, but ideally twice on separate occasions. If systolic is 140-159 or diastolic is 90-99, combined contraception is Category 3. If systolic is 160 or greater or diastolic is 100 or greater, it is Category 4.

Personal history of VTE, stroke, or myocardial infarction. Any history of these events is Category 4.

Family history of VTE before age 45 in a first-degree relative. This suggests possible hereditary thrombophilia. Consider thrombophilia testing before initiation, or choose a non-estrogen method.

Migraine history with specific attention to aura. Ask about visual symptoms, sensory symptoms, or language disturbance preceding headaches.

Smoking status. If over 35 and smoking, quantify cigarettes per day. Fifteen or more is Category 4. Fewer than 15 is Category 3.

BMI. Obesity increases baseline VTE risk. Combined with oral contraceptive use, the risk is multiplicative.

The visit should take longer than five minutes. If it does not, the assessment was incomplete.

At your next visit, bring this list of questions for your physician: What is my blood pressure today? Do I have any Category 3 or Category 4 contraindications to estrogen? If I use combined contraception, which progestin type carries the lowest VTE risk? What are my non-estrogen alternatives if I have risk factors?

Print this article. Hand it to your provider. Ask for the specific answers that determine whether hormonal contraception is safe for your body.

Frequently Asked Questions

Does birth control increase heart attack risk?

Combined oral contraceptives increase myocardial infarction risk, but the absolute magnitude is small in healthy young women. The 2025 BMJ prospective cohort found 3.2 additional MI events per 100,000 person-years among COC users compared to non-users. For context, this means approximately 3 extra heart attacks per year per 100,000 women using the pill. The risk concentrates in women over 35 who smoke, have uncontrolled hypertension, or have diabetes with vascular complications. For healthy non-smoking women under 35, the absolute risk increase is negligible. Progestin-only methods show no increased MI risk in any population studied.

Which birth control is safest for heart health?

Progestin-only methods and the copper IUD carry no increased cardiovascular risk. Among progestin-only options, the levonorgestrel IUD (Mirena, Liletta) combines high contraceptive efficacy with cardiovascular neutrality. The etonogestrel implant (Nexplanon) shows similar safety. If you require estrogen-containing contraception and have no contraindications, levonorgestrel-containing combined pills have the lowest VTE risk at 6-8 per 10,000 woman-years. Avoid drospirenone and desogestrel formulations unless you have specific reasons requiring those progestins.

Can I take birth control pills if I have migraines?

The answer depends entirely on whether you have aura. Migraine without aura permits combined oral contraceptive use in women under 35 who do not smoke, though close monitoring is appropriate. Migraine with aura is an absolute contraindication to estrogen. The stroke risk in women with aura using COCs is 6.1 times higher than in non-users without aura. Visual disturbances, sensory changes, or language difficulties before headaches indicate aura. If you are uncertain whether your migraines include aura, consult a neurologist for clarification before starting or continuing estrogen-containing contraception.

Does the type of progestin in my pill affect blood clot risk?

Yes, significantly. Levonorgestrel-containing pills produce 6-8 VTE events per 10,000 woman-years. Drospirenone-containing pills (Yasmin, Yaz) produce 10-12 events per 10,000 woman-years. Desogestrel-containing pills show similar elevated risk. This represents a 50% higher clot rate with newer progestins compared to levonorgestrel. The difference exists because newer progestins have weaker androgenic effects, which paradoxically increases thrombin generation. If you need combined contraception, choose a levonorgestrel formulation unless you have specific medical reasons for alternative progestins.

Should I stop birth control before surgery?

Stop combined oral contraceptives 4-6 weeks before major surgery involving prolonged immobilization. This applies to orthopedic procedures, major abdominal surgery, and any surgery requiring extended bed rest. The hypercoagulable state from estrogen combined with surgical immobility creates unacceptable VTE risk. Progestin-only methods do not require discontinuation before surgery. The copper IUD obviously has no surgical implications. Plan with your surgeon and gynecologist together. If surgery is urgent and you cannot stop contraception in advance, discuss perioperative thromboprophylaxis with your surgical team.